Clinical trial

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

NCT01291667

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-05-01

PhaseN/A

Study timeline

Study start (unknown)2009-05-01Date precision: month

Registry last updated2011-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Progress-free Survivalunresolved

Overall Response Rateunresolved

Adverse Eventsunresolved

Interventions

Sponsors & collaborators

Shanghai CP Guojian Pharmaceutical Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01291667 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.